Literature DB >> 28057523

Surface engineering tumor cells with adjuvant-loaded particles for use as cancer vaccines.

Kawther K Ahmed1, Sean M Geary1, Aliasger K Salem2.   

Abstract

Cell surface engineering is an expanding field and whilst extensive research has been performed decorating cell surfaces with biomolecules, the engineering of cell surfaces with particles has been a largely unexploited area. This study reports on the assembly of cell-particle hybrids where irradiated tumor cells were surface engineered with adjuvant-loaded, biodegradable, biocompatible, polymeric particles, with the aim of generating a construct capable of functioning as a therapeutic cancer vaccine. Successfully assembled cell-particle hybrids presented here comprised either melanoma cells or prostate cancer cells stably adorned with Toll-like receptor-9 ligand-loaded particles using streptavidin-biotin cross-linking. Both cell-particle assemblies were tested in vivo for their potential as therapeutic cancer vaccines yielding promising therapeutic results for the prostate cancer model. The ramifications of results obtained for both tumor models are openly discussed.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer vaccines; Cell surface engineering; PLGA particles; Streptavidin-biotin cross-linking

Mesh:

Substances:

Year:  2017        PMID: 28057523      PMCID: PMC5309920          DOI: 10.1016/j.jconrel.2016.12.036

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  39 in total

Review 1.  Update on prostate cancer vaccines.

Authors:  Charles G Drake
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

2.  An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow.

Authors:  M B Lutz; N Kukutsch; A L Ogilvie; S Rössner; F Koch; N Romani; G Schuler
Journal:  J Immunol Methods       Date:  1999-02-01       Impact factor: 2.303

3.  Long circulating nanoparticles via adhesion on red blood cells: mechanism and extended circulation.

Authors:  Elizabeth Chambers; Samir Mitragotri
Journal:  Exp Biol Med (Maywood)       Date:  2007-07

4.  Enzyme-functionalized vascular grafts catalyze in-situ release of nitric oxide from exogenous NO prodrug.

Authors:  Zhihong Wang; Yaxin Lu; Kang Qin; Yifan Wu; Yingping Tian; Jianing Wang; Jimin Zhang; Jingli Hou; Yun Cui; Kai Wang; Jie Shen; Qingbo Xu; Deling Kong; Qiang Zhao
Journal:  J Control Release       Date:  2015-05-22       Impact factor: 9.776

5.  Biodegradable particles as vaccine delivery systems: size matters.

Authors:  Vijaya B Joshi; Sean M Geary; Aliasger K Salem
Journal:  AAPS J       Date:  2012-10-10       Impact factor: 4.009

Review 6.  CpG DNA as a vaccine adjuvant.

Authors:  Christian Bode; Gan Zhao; Folkert Steinhagen; Takeshi Kinjo; Dennis M Klinman
Journal:  Expert Rev Vaccines       Date:  2011-04       Impact factor: 5.217

7.  Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

Authors:  Alfons J M van den Eertwegh; Jurjen Versluis; H Pieter van den Berg; Saskia J A M Santegoets; R Jeroen A van Moorselaar; Tim M van der Sluis; Helen E Gall; Thomas C Harding; Karin Jooss; Israel Lowy; Herbert M Pinedo; Rik J Scheper; Anita G M Stam; B Mary E von Blomberg; Tanja D de Gruijl; Kristen Hege; Natalie Sacks; Winald R Gerritsen
Journal:  Lancet Oncol       Date:  2012-02-10       Impact factor: 41.316

8.  Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer.

Authors:  Dung T Le; Eric Lutz; Jennifer N Uram; Elizabeth A Sugar; Beth Onners; Sara Solt; Lei Zheng; Luis A Diaz; Ross C Donehower; Elizabeth M Jaffee; Daniel A Laheru
Journal:  J Immunother       Date:  2013-09       Impact factor: 4.456

9.  DNA vaccination for prostate cancer: key concepts and considerations.

Authors:  Grace Cole; Joanne McCaffrey; Ahlam A Ali; Helen O McCarthy
Journal:  Cancer Nanotechnol       Date:  2015-07-02

Review 10.  Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines.

Authors:  Lien Vandenberk; Jochen Belmans; Matthias Van Woensel; Matteo Riva; Stefaan W Van Gool
Journal:  Front Immunol       Date:  2016-01-14       Impact factor: 7.561

View more
  4 in total

1.  Immunogenic Cell Death Amplified by Co-localized Adjuvant Delivery for Cancer Immunotherapy.

Authors:  Yuchen Fan; Rui Kuai; Yao Xu; Lukasz J Ochyl; Darrell J Irvine; James J Moon
Journal:  Nano Lett       Date:  2017-11-22       Impact factor: 11.189

Review 2.  Advances in Immunotherapy for Melanoma: A Comprehensive Review.

Authors:  Carmen Rodríguez-Cerdeira; Miguel Carnero Gregorio; Adriana López-Barcenas; Elena Sánchez-Blanco; Beatriz Sánchez-Blanco; Gabriella Fabbrocini; Brunilda Bardhi; Ardiana Sinani; Roberto Arenas Guzman
Journal:  Mediators Inflamm       Date:  2017-08-01       Impact factor: 4.711

Review 3.  PLGA-Based Nanoparticles in Cancer Treatment.

Authors:  Sima Rezvantalab; Natascha Ingrid Drude; Mostafa Keshavarz Moraveji; Nihan Güvener; Emily Kate Koons; Yang Shi; Twan Lammers; Fabian Kiessling
Journal:  Front Pharmacol       Date:  2018-11-02       Impact factor: 5.810

4.  Encapsulating Polyethyleneimine-DNA Nanoplexes into PEGylated Biodegradable Microparticles Increases Transgene Expression In Vitro and Reduces Inflammatory Responses In Vivo.

Authors:  Treniece L Terry; Brittany E Givens; Andrea Adamcakova-Dodd; Peter S Thorne; Victor G J Rodgers; Aliasger K Salem
Journal:  AAPS PharmSciTech       Date:  2021-02-09       Impact factor: 3.246

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.